Saman Maleki, PhD, Western University, London, Canada, discusses the correlation between the composition of the gut microbiota with anti-PD-1 efficacy in cancer patients. The gut microbiome composition appears to be correlated with response to immunotherapy with immune checkpoint inhibitors (ICI’S) and the gut microbiome of patients who are respond seem to be more similar to one another compared to patients who do not respond.. Recent studies have additionally shown that the composition of the microbiome is important in regard to toxicity related to immunotherapy. This lead to the hypothesis that the gut microbiome may be important in response to ICI’s, and prospectively changing the gut microbiome may improve patient response to ICI’s. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
